Clinical trial
ZK-Epo Given With Carboplatin in Patients With Recurrent Ovarian Cancer
NCT00325351 · Bayer, Industry · Completed
Key facts
| NCT number | NCT00325351 |
|---|---|
| Title | ZK-Epo Given With Carboplatin in Patients With Recurrent Ovarian Cancer |
| Official title | Phase 1/2 Study of ZK-Epothilone (ZK-Epo; ZK-219477) in Combination With Carboplatin in Patients With Platinum-sensitive Recurrent Ovarian Cancer |
| Lead sponsor | Bayer, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ovarian Neoplasms |
| Intervention type | Drug |
| Interventions | Sagopilone (ZK 219477) + carboplatin |
| Enrollment | 45 |
| Start date | Aug 24, 2006 |
| Primary completion | Jul 8, 2008 |
| Completion | Mar 25, 2009 |
| First posted | May 12, 2006 |
| Last update posted | Apr 8, 2021 |
| Countries | Canada, United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: